Henlius
Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
Henlius, founded in February, 2010 and headquartered in Shanghai, is a medical company involved in tumors and autoimmune diseases. The founder is Chen Qiyu. Listed on the HKEX on September 25, 2019, the company's major shareholders are Shanghai Fosun New Medicine Research Co., Ltd., Henlius Biopharmaceuticals Inc. and Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. Rivals that have direct and indirect competition with Henlius include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Levostar Completes Pre-A Financing Round to Further Invest in CGT
Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
East China medicine "liraglutide" goes to sea
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit